2027 ICD-10-CM Diagnosis Code C60.1Malignant neoplasm of glans penis
ICD-10-CM Codes›C00–D49›C60-C63›C60
- Billable — Valid for Submission
- Risk Adjusts — HCC 23
- Chronic Condition
C60.1 is a billable ICD-10-CM diagnosis code for malignant neoplasm of glans penis. It is valid on HIPAA claims for fiscal year 2027 (October 1, 2026 through September 30, 2027) and groups to MS-DRG 715 through 716, 722 through 724. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under Male reproductive system cancers - penis.
For Medicare Advantage risk adjustment, C60.1 maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors) under the V28 model, adding a risk factor of about 0.186 for a community, non-dual, aged beneficiary in payment year 2027.
Code Identity
Code Classification
Medicare Risk Adjustment (HCC)Billing
C60.1 maps to a payment category in the CMS-HCC model used to risk-adjust Medicare Advantage payments. Weights are the published community factors for payment year 2027.
Source: CMS Payment Year 2027 risk adjustment mappings and model software. Weights are relative factors, not dollar amounts; a beneficiary's total RAF also includes demographics and interactions. Browse all CMS-HCC categories.
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Carcinoma of glans penis
- Carcinoma of penis
- Malignant neoplasm of corpus spongiosum of penis
- Malignant neoplasm of glans penis
- Primary carcinoma of glans penis
- Primary carcinoma of penis
- Primary malignant neoplasm of body of penis
- Primary malignant neoplasm of glans penis
- Primary malignant neoplasm of penis
- Primary squamous cell carcinoma of body of penis
- Primary squamous cell carcinoma of glans penis
- Squamous cell carcinoma of male genital
Instructional NotesGuidance
Instructions from the official ICD-10-CM Tabular List that apply to C60.1: its own notes plus those printed at block C60-C63 and Chapter 2. A note printed at a category, block or chapter applies to every code under it.
Includes
Further defines, or gives examples of, the content of the category.
- malignant neoplasm of skin of male genital organs
Notes
General instructions on how these codes are used.
- Functional activity
- All neoplasms are classified in this chapter, whether they are functionally active or not. An additional code from Chapter 4 may be used, to identify functional activity associated with any neoplasm.
- Morphology [Histology]
- Chapter 2 classifies neoplasms primarily by site (topography), with broad groupings for behavior, malignant, in situ, benign, etc. The Table of Neoplasms should be used to identify the correct topography code. In a few cases, such as for malignant melanoma and certain neuroendocrine tumors, the morphology (histologic type) is included in the category and codes.
- Primary malignant neoplasms overlapping site boundaries
- A primary malignant neoplasm that overlaps two or more contiguous (next to each other) sites should be classified to the subcategory/code .8 ('overlapping lesion'), unless the combination is specifically indexed elsewhere. For multiple neoplasms of the same site that are not contiguous, such as tumors in different quadrants of the same breast, codes for each site should be assigned.
- Malignant neoplasm of ectopic tissue
- Malignant neoplasms of ectopic tissue are to be coded to the site mentioned, e.g., ectopic pancreatic malignant neoplasms are coded to pancreas, unspecified (C25.9).
Source: CMS ICD-10-CM Tabular List. How to read instructional notes.
Referenced in Other NotesGuidance
Instructional notes printed at other codes that name C60.1, its category, or a range that includes it.
Applicable To 2
These notes mention C60.1.
Excludes1 1
These codes carry an Excludes1 note naming C60.1: they are not reported together with it, unless the two conditions are unrelated.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Malignant Penile Neoplasm
a primary or metastatic malignant neoplasm that affects the penis. representative examples include penile carcinoma and penile sarcoma.
Table of NeoplasmsClinical
Patient EducationClinical
Cancer
Cancer is not just one disease but many diseases. Cancer begins in your cells, which are the building blocks of your body. Usually, your body forms new cells as needed, replacing old cells that die. Sometimes this process goes wrong. New cells grow even when you don't need them, and old cells don't die when they should.
The full article covers:
- What is cancer?
- What are the types of cancer?
- How does cancer develop?
- What are the symptoms of cancer?
- How is cancer diagnosed?
- What are the treatments for cancer?
- Can cancer be prevented?
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert C60.1 to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About C60.1Overview
What is the ICD-10 code for malignant neoplasm of glans penis?
The ICD-10-CM code for malignant neoplasm of glans penis is C60.1 (sometimes written as C601). It is billable on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
Is C60.1 (Malignant neoplasm of penis) a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report malignant neoplasm of glans penis on HIPAA-covered claims from October 1, 2026 through September 30, 2027.
What MS-DRG does C60.1 group to?
When malignant neoplasm of glans penis is the principal diagnosis on an inpatient stay, it groups to MS-DRG 716, 723, 724, 715, 722, with relative weights from 0.5709 to 2.2896 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of C60.1?
Under the General Equivalence Mappings, malignant neoplasm of glans penis converts to ICD-9-CM 187.2 (malig neo glans penis). The mapping is a direct match.
What HCC is C60.1?
C60.1 (malignant neoplasm of glans penis) maps to CMS-HCC Category 23 (Prostate, Breast, and Other Cancers and Tumors), commonly written as HCC 23, in the CMS-HCC V28 model used for Medicare Advantage risk adjustment in payment year 2027. It mapped to HCC 12 under the retired V24 model. It also maps in the PACE (CMS-HCC V22), ESRD (V21), and ESRD (V24) models. In the Part D prescription drug model it maps to RxHCC 22.
Does C60.1 risk-adjust for Medicare Advantage payment?
Yes. When documented and reported on a Medicare Advantage encounter, C60.1 adds a risk adjustment factor of about 0.186 to the beneficiary's RAF score for a community, non-dual, aged enrollee (published V28 weights range from 0.186 to 0.237 depending on the payment segment). A more severe related category (HCC 17, HCC 18, HCC 19, HCC 20, HCC 21, and HCC 22) supersedes it when both are reported. See the full factor table on the HCC 23 category page.